Most researchers searching for CJC-1295 in Rinn quickly find that local retail options are essentially nonexistent. This online-only market structure is actually an advantage for quality — top vendors compete on lab-verified purity in ways local stores never could. What reliably differentiates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety documentation. This guide gives Rinn researchers the framework to assess vendor quality rigorously and source verified-quality CJC-1295 with confidence.
The Science Behind CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Rinn studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
CJC-1295 Purchasing Guide
Vetting CJC-1295 vendors requires starting from the COA: access the batch-specific certificate before purchasing, not after. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are at acceptable levels for the intended application. Red flags in CJC-1295 vendor evaluation: prices far under typical market pricing, unclear production details, no community presence, and COAs that lack endotoxin data. Store lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Rinn
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the risk characterisation for this compound is based on research literature rather than clinical trials. Temperature excursions — even brief warming above recommended storage temperature — can partially degrade CJC-1295 without any obvious sign; always verify cold chain was maintained during shipping. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results expressed as EU/mg or EU/mL and verify they are within the acceptable range for your research context. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is not a licensed human medication and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
